Edition:
United Kingdom

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

146.60USD
6:13pm GMT
Change (% chg)

$-2.70 (-1.81%)
Prev Close
$149.30
Open
$148.88
Day's High
$149.53
Day's Low
$145.89
Volume
237,424
Avg. Vol
718,980
52-wk High
$197.00
52-wk Low
$125.84

Chart for

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US... (more)

Overall

Beta: 1.17
Market Cap(Mil.): $69,117.80
Shares Outstanding(Mil.): 334.31
Dividend: 0.70
Yield (%): 1.35

Financials

  AGN.N Industry Sector
P/E (TTM): -- 29.30 32.54
EPS (TTM): -11.66 -- --
ROI: -3.08 14.23 13.82
ROE: -5.61 15.46 15.24

Hedge fund Appaloosa unimpressed by Allergan board promises

Activist investor Appaloosa LP responded to proposed concessions from the board of Allergan Plc by saying it had done everything "except what needs to be done" and calling on other investors to take further "disruptive" steps to change the company.

12:02pm GMT

Hedge fund Appaloosa unimpressed by Allergan board promises

March 25 Activist investor Appaloosa LP responded to proposed concessions from the board of Allergan Plc by saying it had done everything "except what needs to be done" and calling on other investors to take further "disruptive" steps to change the company.

11:53am GMT

RPT-UPDATE 2-Allergan promises independent board chair in next leadership change

March 22 Allergan Plc on Friday agreed to split its chairman and chief executive roles, but only at its next leadership change, as the drugmaker pushed back against claims from activist hedge fund Appaloosa LP that an independent chair could help current CEO Brent Saunders boost the company's sagging share price.

23 Mar 2019

UPDATE 2-Allergan promises independent board chair in next leadership change

March 22 Allergan Plc on Friday agreed to split its chairman and chief executive roles, but only at its next leadership change, as the drugmaker pushed back against claims from activist hedge fund Appaloosa LP that an independent chair could help current CEO Brent Saunders boost the company's sagging share price.

22 Mar 2019

Allergan promises independent board chair in next leadership change

Allergan Plc plans to elect an independent board chairman, starting with the next leadership transition, the Botox maker said on Friday, as the drugmaker responds to calls from hedge fund Appaloosa LP to separate the roles of chairman and chief executive officer.

22 Mar 2019

Allergan plans independent board chairman

March 22 Allergan Plc said on Friday its board chairman shall be an independent member, starting with the next leadership transition.

22 Mar 2019

Appaloosa steps up pressure on Allergan after failed drug trials

Hedge fund Appaloosa LP on Thursday repeated its call for an independent chairman at Allergan Plc, after the Botox producer revealed that one of its drugs had failed three clinical studies.

07 Mar 2019

UPDATE 1-Appaloosa steps up pressure on Allergan after failed drug trials

March 7 Hedge fund Appaloosa LP on Thursday repeated its call for an independent chairman at Allergan Plc , after the Botox producer revealed that one of its drugs had failed three clinical studies.

07 Mar 2019

Appaloosa steps up pressure on Allergan after failed depression drug trials

March 7 Hedge fund Appaloosa LP on Thursday reiterated its call for an independent chairman at Allergan Plc's board, after the Botox-maker said its depression treatment failed three late-stage studies.

07 Mar 2019

Allergan depression treatment fails studies, shares slip

Allergan Plc said on Wednesday its experimental add-on treatment for depression failed three late-stage studies, casting doubts over its drugs pipeline and sending the Botox-maker's shares down nearly 4 percent after the bell.

06 Mar 2019

Earnings vs. Estimates